© Rosalind Scientific LLC 2018-2022
New Drug Hunter content, featured events and job postings straight to your inbox. Trusted by >4,000 drug hunters worldwide, unsubscribe anytime.
Home > GNF2133
<< Back to February
GSK3β-sparing DYRK1A kinase inhibitor
orally efficacious in proliferation model, but non-specific proliferation observed
from cellular phenotypic screen and opt.
J. Med. Chem. Feb. 20, 2020
Novartis (GNF), San Diego, CA
GNF2133 (Novartis (GNF) oral in vivo GSK3-beta-sparing DYRK1A kinase inhibitor)
Unlock this content with a Premium membership to read it now.